Viewing data from:

DEXTROMETHORPHAN POLISTIREX

ANDA

DEXTROMETHORPHAN POLISTIREX | A091135 | TRIS PHARMA INC

1 strength0 unique patents0 unique exclusivities

Drug Pricing (NADAC)

National Average Drug Acquisition Cost — Week of 2026-07-15 | 12 NDCs

Highest NADAC/Unit

$0.0681

per ml

Lowest NADAC/Unit

$0.0527

per ml

Brand NDCs

Generic NDCs

NDC Description	NADAC/Unit	Unit	Type	Generic NADAC	Effective
70000030201COUGH DM ER 30 MG/5 ML SUSP	$0.0681	ML	Generic	—	2026-06-17
00904631256COUGH DM ER 30 MG/5 ML SUSP	$0.0681	ML	Generic	—	2026-06-17
46122014121COUGH DM ER 30 MG/5 ML SUSP	$0.0681	ML	Generic	—	2026-06-17
70000019501CHILD COUGH DM ER 30 MG/5 ML	$0.0681	ML	Generic	—	2026-06-17
70677102501FT 12-HR COUGH RLF 30 MG/5 ML	$0.0681	ML	Generic	—	2026-06-17
70677102601FT 12-HR COUGH RLF 30 MG/5 ML	$0.0681	ML	Generic	—	2026-06-17

Showing 6 of 12 NDCs.

Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.

VA Federal Supply Schedule

Government-negotiated contract prices | 2 NDCs (2 FSS)

Lowest Price

$4.71

Highest Price

$5.29

FSS NDCs

Big4 NDCs

Description	Price	Type	Vendor	Contract End
00904-6312-56DEXTROMETHORPHAN 30MG/5ML LIQUID	$5.29	FSS	The Harvard Drug Group L.L.C. dba Major Pharmaceuticals and Rugby Labs	05/31/2030
00113-0958-21DEXTROMETHORPHAN 30MG/5ML SUSP,SA	$4.71	FSS	Golden State Medical Supply, Inc.	06/14/2028

Source: VA Federal Supply Schedule (va.gov). Prices are government-negotiated contract prices.

API Supply Chain3 active DMFs1 inactive

3 active API suppliers hold Drug Master Files for this ingredient.

SOLARA ACTIVE PHARMA SCIENCES LTDDEXTROMETHORPHAN POLISTIREX

DMF 292162015

APITORIA PHARMA PRIVATE LTDDEXTROMETHORPHAN POLISTIREX

DMF 379102022

DASAMI LAB PRIVATE LTDDEXTROMETHORPHAN POLISTIREX

DMF 412862025

CAMBREX CHARLES CITY INCInactiveDEXTROMETHORPHAN POLISTIREX

DMF 223292008

Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.

Approval Letters

1 letter from Drugs@FDA

Date	Submission	Document
May 30, 2012	ORIG -1	View Letter (PDF)

Source: Drugs@FDA application documents.

Products (1)

#001 — EQ 30MG HYDROBROMIDE/5ML

0 patents0 exclusivities▴

SUSPENSION, EXTENDED RELEASE;ORAL | Approved: May 25, 2012

No patent or exclusivity listings for this strength.